Lafyatis
David S. Lafyatis, Schaumburg, IL US
Patent application number | Description | Published |
---|---|---|
20130066123 | PROCESS FOR TRANSALKYLATING AROMATIC HYDROCARBONS - The present invention is a process for transalkylating aromatic hydrocarbon compounds, the process comprising introducing an aromatic hydrocarbon feed stream into a transalkylation zone to yield high-purity benzene as a byproduct while meeting transalkylation objectives. The feed stream contacts a catalyst in the transalkylation zone under conditions adjusted to control benzene purity as well as transalkylation performance. | 03-14-2013 |
20140100403 | LOW PRESSURE TRANSALKYLATION PROCESS - A process for transalkylation is described. The process operates at a lower pressure than a typical transalkylation processes, and provides higher benzene purity with comparable or lower ring loss compared to the typical transalkylation process. The xylene selectivity is comparable to or higher than the standard process, and the ethyl benzene selectivity is comparable to or lower than the standard process. | 04-10-2014 |
Robert A. Lafyatis, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20110189682 | TOOLS FOR OBJECTIVELY DETERMINING SEVERITY OF SYSTEMIC SCLEROSIS - Methods are disclosed for the identification and use of biomarkers in order to objectively measure systemic sclerosis. The biomarker may be a single gene, or may be a combination of multiple genes. A preferred embodiment in which the biomarker is a four gene combination of two TGFβ regulated genes (COMP and THS1), and two IFN regulated genes (IFI44 and SIG1) is the best identified predictor of systemic sclerosis as measured by the modified Rodnan skin score. | 08-04-2011 |
Robert Alan Lafyatis, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20160120865 | TOPICAL TREATMENT OF LOCALIZED SCLERODERMA - Disclosed are compositions and formulations for topical administration that contain a tyrosin kinase inhibitor, such as imatinib or nilotinib. The topical compositions or formulations are useful in treating scleroderma. | 05-05-2016 |